Improved Survival in Patients with Peritoneal Metastases from Colorectal Cancer: a Preliminary Study

Overview

Journal Br J Cancer

Specialty Oncology

Date 2004 Jan 22

PMID 14735184

Citations 40

Authors

H Mahteme

J Hansson

A Berglund

L Pahlman

B Glimelius

P Nygren

W Graf

Affiliations

Soon will be listed here.

Abstract

Patients with peritoneal or local metastases from colorectal cancer have a poor prognosis. However, aggressive treatments by debulking surgery and infusional intraperitoneal (i.p.) chemotherapy have been tried and appear to benefit selected patients. We assayed the effects of debulking surgery and i.p. chemotherapy with respect to survival and compared the results with matched control patients treated by intravenous (i.v.) chemotherapy. In all, 18 patients with peritoneal and/or local metastases from colorectal adenocarcinoma underwent debulking surgery followed by 5-fluorouracil (5-FU) 550 mg m(-2) day(-1) i.p. and leucovorin (LV) 60 mg m(-2) day(-1) i.v. The chemotherapy was started the day after surgery and was given daily for 6 days and repeated monthly for totally eight courses. The control patients, matched for age, gender, performance status and metastatic site, were randomly selected from controlled clinical chemotherapy trials and treated with i.v. 5-FU+LV or i.v. methotrexate+5-FU+LV. There was no treatment-related mortality. The median survival among i.p. patients was 32 months compared to 14 months in the control group. In all, 11 patients who underwent macroscopically radical surgery had a longer survival than those who were not radically operated (P=0.02). These results indicate that patients with peritoneal metastases and/or locally advanced cancers but without distant metastases may benefit from cytoreductive surgery combined with i.p. chemotherapy.

Citing Articles

Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.

Cyrelle Ornella M, Badrinath N, Kim K, Kim J, Cho E, Hwang T Cancers (Basel). 2023; 15(8).

PMID: 37190310 PMC: 10137063. DOI: 10.3390/cancers15082383.

First experience with Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study).

Larsen S, Graf W, Mariathasan A, Sorensen O, Spasojevic M, Goscinski M Front Med (Lausanne). 2023; 10:1070362.

PMID: 36936230 PMC: 10016379. DOI: 10.3389/fmed.2023.1070362.

Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer.

Kim Y, Kim C Ann Coloproctol. 2021; 37(6):425-433.

PMID: 34961304 PMC: 8717073. DOI: 10.3393/ac.2021.00920.0131.

Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.

Larsen S, Goscinski M, Dueland S, Steigen S, Hofsli E, Torgunrud A Br J Cancer. 2021; 126(5):726-735.

PMID: 34887523 PMC: 8888568. DOI: 10.1038/s41416-021-01620-6.

Cancer follow-up supported by patient-reported outcomes in patients undergoing intended curative complex surgery for advanced cancer.

Ravn S, Thaysen H, Verwaal V, Seibaek L, Iversen L J Patient Rep Outcomes. 2021; 5(1):120.

PMID: 34748095 PMC: 8575728. DOI: 10.1186/s41687-021-00391-1.

References

Stephens A, Alderman R, Chang D, Edwards G, Esquivel J, Sebbag G . Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 2000; 6(8):790-6. DOI: 10.1007/s10434-999-0790-0. View

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

Germann U . Detection of recombinant P-glycoprotein in multidrug resistant cultured cells. Mol Biotechnol. 2000; 14(2):131-45. DOI: 10.1385/MB:14:2:131. View

Sugarbaker P, Schellinx M, Chang D, Koslowe P, von Meyerfeldt M . Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg. 1996; 20(5):585-91; discussion 592. DOI: 10.1007/s002689900091. View

Leunig M, Goetz A, Dellian M, Zetterer G, Gamarra F, Jain R . Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992; 52(2):487-90. View

Shepherd N, Baxter K, Love S . The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology. 1997; 112(4):1096-102. DOI: 10.1016/s0016-5085(97)70119-7. View

Keppler D, Kamisako T, Leier I, Cui Y, Nies A, Tsujii H . Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family. Adv Enzyme Regul. 2000; 40:339-49. DOI: 10.1016/s0065-2571(99)00022-9. View

Saltz L, Cox J, Blanke C, Rosen L, Fehrenbacher L, Moore M . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343(13):905-14. DOI: 10.1056/NEJM200009283431302. View

Graf W, Weiber S, Jiborn H, Pahlman L, Glimelius B, Zederfeldt B . The roles of nutritional depletion and drug concentration in 5-fluorouracil-induced inhibition of colonic healing. J Surg Res. 1994; 56(5):452-6. DOI: 10.1006/jsre.1994.1071. View

10.

Schellinx M, Von Meyenfeldt M, Sugarbaker P . Peritoneal carcinomatosis from adenocarcinoma of the colon. Cancer Treat Res. 1996; 81:247-60. DOI: 10.1007/978-1-4613-1245-1_21. View

11.

Vaillant J, Nordlinger B, Deuffic S, Arnaud J, Pelissier E, Favre J . Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial. Ann Surg. 2000; 231(4):449-56. PMC: 1421018. DOI: 10.1097/00000658-200004000-00001. View

12.

Graf W, Westlin J, Pahlman L, Glimelius B . Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study. Int J Colorectal Dis. 1994; 9(1):35-9. DOI: 10.1007/BF00304298. View

13.

Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209):1041-7. DOI: 10.1016/s0140-6736(00)02034-1. View

14.

Wright S, Boag A, Valdimarsson G, Hipfner D, Campling B, Cole S . Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res. 1998; 4(9):2279-89. View

15.

Glimelius B, Jakobsen A, Graf W, Berglund A, Gadeberg C, Hansen P . Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer. 1998; 34(5):674-8. DOI: 10.1016/s0959-8049(97)10055-7. View

16.

Graf W, Glimelius B, Pahlman L, Bergstrom R . Determinants of prognosis in advanced colorectal cancer. Eur J Cancer. 1991; 27(9):1119-23. DOI: 10.1016/0277-5379(91)90307-y. View

17.

Glimelius B . Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic.... Ann Oncol. 1993; 4(3):235-40. DOI: 10.1093/oxfordjournals.annonc.a058463. View

18.

Glimelius B . Palliative treatment of patients with colorectal cancer. Scand J Surg. 2003; 92(1):74-83. DOI: 10.1177/145749690309200111. View

19.

van Ooijen B, van der Burg M, Planting A, Siersema P, Wiggers T . Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet. 1993; 176(5):469-74. View

20.

Csoka K, Nygren P, Graf W, Pahlman L, Glimelius B, Larsson R . Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. Int J Cancer. 1995; 63(3):356-60. DOI: 10.1002/ijc.2910630309. View